Sygnis sells its own-brand TruePrime and SunScript kits through its website and an international distributor network. A rights issue for €6.7m plus a €0.6m debt conversion was announced on 17 November. This will allow Sygnis to develop its brand, extend its product range of kits and enter the crucial US market. Kits may also be sold as OEM products for next-generation sequencing. A kit for cell-free DNA “liquid biopsy” analysis, a high growth area, is planned for 2016. Cash at 30 September was €0.6m with a €0.3m loan payment due by the year end.
